Research paperReduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4☆
References (18)
- et al.
Evaluation of implant materials (hydroxyapatite, glass-ceramics, titanium) in rat bone marrow stromal cell culture
Biomaterials
(1996) - et al.
The specific type IV phosphodiesterase inhibitors rolipram suppress TNFa production by human mononuclear cells
Int J Immunopharmacol
(1993) - et al.
Expression of prostagalndin E receptor subtypes in bone: Expression of EP2 in bone development
Bone
(1995) - et al.
Epidemiology of osteoporosis: Implication for drug therapy
Drugs Aging
(1995) - et al.
Osteoporosislike changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormonerelated protein production
Jpn J Cancer Res
(1995) - et al.
The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site
Br J Pharmacol
(1989) - et al.
Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats
Cell Tissue Res
(1988) Bone marrow stromal cell culture as a bone formative experimental system: Technical points and applications to bone research
- et al.
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures
Endocrinology
(1988)
Cited by (43)
Cilomilast enhances osteoblast differentiation of mesenchymal stem cells and bone formation induced by bone morphogenetic protein 2
2012, BiochimieCitation Excerpt :Although several studies have reported that the possibility to use agents capable of increasing the effect of BMPs, the mechanisms on these effects are uncertain [6–9]. In different experimental osteopaenia models, therapeutic effects were achieved by using specific or nonspecific phosphodiesterase (PDE) inhibitors [10,11]. Sugama et al. [12] studied the combinative effect of PeTx, a nonspecific PDE inhibitor, and BMP-4 on ST2 cells, and suggested that cyclic adenosine monophosphate (cAMP) may be involved in the intensification of the BMPs signalling.
Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts
2007, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Interestingly, it has been reported that rolipram, a selective PDE4 inhibitor, increases systemic bone mass in mice [21]. Other PDE4 inhibitors have also shows therapeutic effects against bone loss in some animal osteopenia models [22,23]. Therefore, PDE4 inhibitors are potential anabolic anti-osteoporosis drugs that could replace PTH.
Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells
2005, Biochemical PharmacologyCitation Excerpt :Several recent studies suggest a role of PDE4 in the regulation of bone metabolism. In rats, inoculated with Walker 256/S carcinoma to induce an artificial osteoporotic state, bone loss was reduced by over 50% after a two-week treatment with the PDE4 selective inhibitor denbufylline [35]. Rolipram, and two novel PDE4 inhibitors XT-44 and XT-611, have been shown to increase mineralized nodule formation [36] and PGE2-mediated anabolic effects [37] in rat bone marrow culture.
- ☆
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.